Approach to the Patient with Nephrotic Syndrome

Chapter

Abstract

A 50-year-old woman with no significant past medical history acutely develops bilateral lower extremity pitting edema. A thorough evaluation of cardiac and hepatic functions is unremarkable; however, urinalysis reveals significant proteinuria. Further testing shows an elevated serum creatinine level of 1.8 mg/dL, low serum albumin level of 2.2 g/dL, and hyperlipidemia (total cholesterol 385 mg/dL, triglycerides 480 mg/dL, LDL 245 mg/dL, and HDL 44 mg/dL). Urinary protein measures 5.2 g in a 24-h collection. The clinical diagnosis of nephrotic syndrome is made.

Keywords

Angiotensin Cyclosporine Proteinuria Statin Triglyceride 

References

  1. 1.
    Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338(17):1202–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008;336(7654):1185–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Bernard DB. Extrarenal complications of the nephrotic syndrome. Kidney Int. 1988;33(6):1184–202.PubMedCrossRefGoogle Scholar
  4. 4.
    Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Genet. 2000;24(4):333–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis. 1996;27(5):647–51.PubMedCrossRefGoogle Scholar
  6. 6.
    Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997;30(5):621–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol. 2006;1(3):483–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175–84.PubMedCrossRefGoogle Scholar
  9. 9.
    D’Agati V. Pathologic classification of focal seg­mental glomerulosclerosis. Semin Nephrol. 2003;23(2):117–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 2006;69(5):920–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Beck Jr LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Padiyar A, Bodziak KA, Hricik DE, Augustine JJ. Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. Am J Transplant. 2010;10(2):310–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit ­diaphragm-associated proteins. Stallone G, Infante B, Pontrelli P, Gigante M, Montemurno E, Loverre A, Rossini M, Schena FP, Grandaliano G, Gesualdo L.Transplantation. 2011 May 15;91(9):997–1004.Google Scholar
  14. 14.
    Loriga G, Ciccarese M, Pala PG, et al. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis. Transplant Proc. 2010;42(4):1297–302.PubMedCrossRefGoogle Scholar
  15. 15.
    Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation. 1999;68(5):635–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant. 2010;14(3):314–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Ballmer PE, Weber BK, Roy-Chaudhury P, et al. Elevation of albumin synthesis rates in nephrotic patients measured with [1–13C]leucine. Kidney Int. 1992;41(1):132–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Praga M, Borstein B, Andres A, et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis. 1991;17(3):330–8.PubMedGoogle Scholar
  19. 19.
    Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;16(9):1790–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Marsh JB. Lipoprotein metabolism in the nephrotic syndrome. Front Biosci. 2002;7:e326–38.PubMedCrossRefGoogle Scholar
  21. 21.
    Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.PubMedGoogle Scholar
  23. 23.
    Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51(2):199–211.PubMedCrossRefGoogle Scholar
  24. 24.
    Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Dharmaraj R, Hari P, Bagga A. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatr Nephrol. 2009;24(4):775–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Vaziri ND, Liang K. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome. Am J Nephrol. 2004;24(6):606–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Olbricht CJ, Wanner C, Thiery J, Basten A. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl. 1999;71:S113–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Appel GB, Waldman M, Radhakrishnan J. New approaches to the treatment of glomerular diseases. Kidney Int. 2006;70(S104):S45–50.CrossRefGoogle Scholar
  29. 29.
    Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704.PubMedCrossRefGoogle Scholar
  30. 30.
    Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol. 2008;3(3):905–19.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Nephrology and HypertensionMayo Clinic ArizonaPhoenixUSA

Personalised recommendations